Sun Pharma to Acquire Organon in All-Cash Deal
AI-generated from multiple sources. Verify before acting on this reporting.
MUMBAI -- Sun Pharmaceutical Industries Ltd. announced on Sunday it has agreed to acquire U.S.-based Organon & Co. in an all-cash transaction, marking one of the largest cross-border mergers in the pharmaceutical sector this year. The deal, valued at approximately $18 billion, is expected to significantly expand Sun Pharma's presence in the women's health and specialty pharmaceuticals markets.
The acquisition agreement was finalized late Sunday, with both companies issuing joint statements confirming the terms. Under the deal, Sun Pharma will pay $65 per share in cash for Organon, representing a premium of roughly 20% over Organon's closing price on Friday. Organon's shares surged more than 18% in after-hours trading following the announcement, reflecting investor confidence in the transaction's strategic value.
Organon, spun off from Merck & Co. in 2021, has built a strong portfolio in women's health, including contraceptives and treatments for menopause and endometriosis. The company also holds significant assets in respiratory and immunology. Sun Pharma, India's largest pharmaceutical company by market capitalization, has been actively seeking to bolster its U.S. portfolio through strategic acquisitions. This move aligns with its long-term strategy to increase its footprint in high-growth therapeutic areas.
The transaction is subject to regulatory approvals and shareholder consent from both companies. Sun Pharma stated that the deal is expected to close in early 2027, pending necessary clearances from antitrust authorities in the United States and India. Both companies have committed to a comprehensive due diligence process to ensure compliance with all applicable laws and regulations.
Organon's board of directors unanimously approved the agreement, citing the offer as a compelling opportunity for shareholders. The company's CEO, Dr. Christopher Boerner, said the partnership would enable Organon to leverage Sun Pharma's global manufacturing capabilities and distribution network. Sun Pharma's Chairman, Dilip Shanghvi, emphasized that the acquisition would accelerate the company's growth trajectory and enhance its ability to deliver innovative medicines to patients worldwide.
The deal comes amid a wave of consolidation in the global pharmaceutical industry, as companies seek to diversify their portfolios and mitigate risks associated with patent expirations. Analysts have noted that the combination could create synergies in research and development, potentially leading to faster drug development cycles and reduced costs.
However, the transaction faces potential hurdles. Regulatory scrutiny is expected to be intense, particularly in the United States, where antitrust authorities have been increasingly cautious about large pharmaceutical mergers. The Federal Trade Commission and the Department of Justice will likely review the deal to ensure it does not reduce competition in key therapeutic areas.
Additionally, shareholder approval is required from both companies. While Organon's board has endorsed the deal, individual shareholders may have differing opinions on the valuation and strategic fit. Sun Pharma will need to secure sufficient support to finalize the acquisition.
As the companies move forward with regulatory filings and due diligence, the market will be watching closely for any updates on the deal's progress. The outcome of this acquisition could set a precedent for future cross-border mergers in the pharmaceutical sector.